Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data

Grigoriou, Antigoni; Ibrahim, Fowzia; Chaabo, Khaldoun; Scott, David; Steer, Sophia; Galloway, James

doi:10.1093/rheumatology/kev386

Cited by 11 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors noted that use of earlier nsNSAIDs -same as celecoxib -in that particular population was reasonably safe. The same conclusions were drawn by British authors assessing NSAID use in rheumatoid arthritis patients [17]. 5.…”

Section: Tab 1 Milestones In Terms Of Cardiovascular Safety Of Non-steroidal Anti-inflammatory Drugssupporting

confidence: 79%

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Alušík¹,

Paluch²

2018

Vnitř Lék

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) belong to the most widely used drugs. Results of recent large meta-analyses have shown that the cardiovascular risk of NSAIDs is more serious than originally believed and is not associated exclusively with coxibs; it is also increased when using so called traditional NSAIDs. Data obtained to date show the safest drugs of this class in terms of cardiovascular risk are naproxen and ibuprofen at low doses. The position of naproxen as the safest NSAID has been challenged by some more recent findings. The authors examine some results of meta-analyses and conclusions of regulatory agencies.

show abstract

Section: Tab 1 Milestones In Terms Of Cardiovascular Safety Of Non-steroidal Anti-inflammatory Drugssupporting

confidence: 79%

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Alušík¹,

Paluch²

2018

Vnitř Lék

View full text Add to dashboard Cite

show abstract

“… 32 – 34 On the contrary, there is no association between use of NSAIDs and CVS risk in patients with RA. 35 One explanation is that the beneficial impact of NSAIDs in lowering systemic inflammatory burden offsets the deleterious vascular effect of COX-2 inhibition. 36 Furthermore, NSAIDs can improve mobility and function in patient with SpA.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs

Chan

Teo

et al. 2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Background: Cardiovascular (CVS) diseases are the leading cause of death worldwide and patients with rheumatic diseases have an increased CVS. CVS risk factors and CVS events are common in spondyloarthritis (SpA). Delineating the CVS risk in patients with SpA and identifying modifiable risk factors would be useful. Methods: Patients with SpA and patients with non-specific back pain (NSBP) were identified in rheumatology and orthopedics clinics, respectively. Clinical information and CVS events were retrieved. Baseline characteristics and incidence rates of CVS events were compared between two groups of patients using an age- and sex-matched cohort. Propensity score adjustment and Cox regression analysis were performed to determine the CVS risk associated with SpA. Results: A total of 5046 patients (SpA 2616 and NSBP 2430) were included from eight centers. Over 56,484 person-years of follow up, 160 strokes, 84 myocardial infarction (MI) and 262 major adverse cardiovascular events (MACE) were identified. Hypercholesterolemia was more prevalent in SpA (SpA 34.2%, NSBP 28.7%, p < 0.01). Crude incidence rates of MACE and stroke were higher in SpA patients. SpA was associated with a higher risk of MACE [hazard ratio (HR) 1.70; 95% confidence interval (CI) 1.29–2.26; p < 0.01] and cerebrovascular events (HR 1.50; 95% CI 1.08–2.07; p = 0.02). SpA patients with anti-TNF use had a reduced risk of MACE (HR 0.37, 95%CI 0.17–0.80, p = 0.01) and cerebrovascular events (HR 0.21, 95%CI 0.06–0.78, p = 0.02) compared with SpA patients without anti-TNF use. Conclusion: SpA is an independent CVS risk factor. Anti-tumor necrosis factor (TNF) drugs were associated with a reduced CVS risk in these patients.

show abstract

“…As long-term oral western medicine has relatively large side effects and single effect, it often needs to be combined with other medicines, [ 7 ] resulting in poor compliance of patients and relatively difficult treatment.…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of Huangqi Guizhi Wuwu decoction for rheumatoid arthritis

et al. 2020

View full text Add to dashboard Cite

Background: Rheumatoid arthritis has the characteristics of slow progression, long course, and repeated attacks. At present, western medicine commonly used in clinical practice not only reduces pain and improves symptoms, but also has more adverse reactions, affecting the health, and life of patients. In ancient China, Huangqi Guizhi Wuwu decoction was used by doctors to treat rheumatoid arthritis, with remarkable effect. In recent years, many clinical studies have also shown that Huangqi Guizhi Wuwu decoction has reliable effect in treating rheumatoid arthritis, but there is no evidence of evidence-based medicine. Therefore, this study aims to systematically evaluate the clinical efficacy and safety of Huangqi Guizhi Wuwu decoction in the treatment of rheumatoid arthritis. Methods: Using computer to retrieve PubMed, The Cochrance Library, Embase, Web of Science, CNKI, VIP and Wanfang database, in addition manually retrieve Google academic and Baidu academic to collect all randomized controlled trials for Huangqi Guizhi Wuwu decoction in the treatment of rheumatoid arthritis, including relevant academic journal and conference papers, dissertations, from the establishment of the database to July 2020. After 2 evaluators independently screened the literature, extracted the data, and evaluated the risk of bias included in the study, RevMan5.3 software was used to analyze the data. Results: This research evaluate the efficacy and safety of Huangqi Guizhi Wuwu decoction in treating Rheumatoid arthritis from the aspects of clinical efficacy rate, visual analog scale (VAS), swollen joint count (SJC), morning stiffness time, Rrythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and adverse reaction incidence. Conclusion: This study will provide reliable evidence for the clinical application of Huangqi Guizhi Wuwu decoction in the treatment of rheumatoid arthritis. Ethics and dissemination: The private information from individuals will not publish. This systematic review also will not involve endangering participant rights. Ethical approval is not required. The results may be published in a peer-reviewed journal or disseminated in relevant conferences. OSF Registration number: DOI 10.17605/OSF.IO/RZY3V.

show abstract

Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data

Cited by 11 publications

References 5 publications

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs

The efficacy and safety of Huangqi Guizhi Wuwu decoction for rheumatoid arthritis

Contact Info

Product

Resources

About